A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia

Edward D. Huey*, Karen T. Putnam, Jordan Grafman

*Corresponding author for this work

Research output: Contribution to journalReview article

186 Citations (Scopus)

Abstract

Objective: To evaluate neurotransmitter deficiencies and neurotransmitter-based treatments for frontotemporal dementia (FTD). Methods: The authors conducted a systematic review of the literature on the mechanism and treatment of FTD and a meta-analysis of treatment studies of antidepressants for the behavioral symptoms of FTD. Results: Patients with FTD show deficiencies in the serotonin and dopamine neurotransmitter systems, while the acetylcholine system appears relatively intact. Antidepressant treatment significantly improves behavioral symptoms in FTD, but most studies are small and uncontrolled. Serotonergic treatments appear to improve the behavioral but not cognitive symptoms of FTD. Conclusions: Studies of neurotransmitter deficiencies in frontotemporal dementia (FTD) can be helpful in developing treatments. Treatment studies on FTD are scarce, given the prevalence and severity of this illness. Larger, well-controlled treatment studies are required to reach more definitive conclusions about treatment efficacy. Multicenter studies are likely the best way to complete treatment studies in a timely manner.

Original languageEnglish (US)
Pages (from-to)17-22
Number of pages6
JournalNeurology
Volume66
Issue number1
DOIs
StatePublished - Jan 1 2006

Fingerprint

Frontotemporal Dementia
Neurotransmitter Agents
Behavioral Symptoms
Therapeutics
Antidepressive Agents
Neurobehavioral Manifestations
Multicenter Studies
Acetylcholine
Meta-Analysis
Dopamine
Serotonin

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Huey, Edward D. ; Putnam, Karen T. ; Grafman, Jordan. / A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. In: Neurology. 2006 ; Vol. 66, No. 1. pp. 17-22.
@article{ee37460acd094c2e967f1d0dcd1f41a1,
title = "A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia",
abstract = "Objective: To evaluate neurotransmitter deficiencies and neurotransmitter-based treatments for frontotemporal dementia (FTD). Methods: The authors conducted a systematic review of the literature on the mechanism and treatment of FTD and a meta-analysis of treatment studies of antidepressants for the behavioral symptoms of FTD. Results: Patients with FTD show deficiencies in the serotonin and dopamine neurotransmitter systems, while the acetylcholine system appears relatively intact. Antidepressant treatment significantly improves behavioral symptoms in FTD, but most studies are small and uncontrolled. Serotonergic treatments appear to improve the behavioral but not cognitive symptoms of FTD. Conclusions: Studies of neurotransmitter deficiencies in frontotemporal dementia (FTD) can be helpful in developing treatments. Treatment studies on FTD are scarce, given the prevalence and severity of this illness. Larger, well-controlled treatment studies are required to reach more definitive conclusions about treatment efficacy. Multicenter studies are likely the best way to complete treatment studies in a timely manner.",
author = "Huey, {Edward D.} and Putnam, {Karen T.} and Jordan Grafman",
year = "2006",
month = "1",
day = "1",
doi = "10.1212/01.wnl.0000191304.55196.4d",
language = "English (US)",
volume = "66",
pages = "17--22",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. / Huey, Edward D.; Putnam, Karen T.; Grafman, Jordan.

In: Neurology, Vol. 66, No. 1, 01.01.2006, p. 17-22.

Research output: Contribution to journalReview article

TY - JOUR

T1 - A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia

AU - Huey, Edward D.

AU - Putnam, Karen T.

AU - Grafman, Jordan

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Objective: To evaluate neurotransmitter deficiencies and neurotransmitter-based treatments for frontotemporal dementia (FTD). Methods: The authors conducted a systematic review of the literature on the mechanism and treatment of FTD and a meta-analysis of treatment studies of antidepressants for the behavioral symptoms of FTD. Results: Patients with FTD show deficiencies in the serotonin and dopamine neurotransmitter systems, while the acetylcholine system appears relatively intact. Antidepressant treatment significantly improves behavioral symptoms in FTD, but most studies are small and uncontrolled. Serotonergic treatments appear to improve the behavioral but not cognitive symptoms of FTD. Conclusions: Studies of neurotransmitter deficiencies in frontotemporal dementia (FTD) can be helpful in developing treatments. Treatment studies on FTD are scarce, given the prevalence and severity of this illness. Larger, well-controlled treatment studies are required to reach more definitive conclusions about treatment efficacy. Multicenter studies are likely the best way to complete treatment studies in a timely manner.

AB - Objective: To evaluate neurotransmitter deficiencies and neurotransmitter-based treatments for frontotemporal dementia (FTD). Methods: The authors conducted a systematic review of the literature on the mechanism and treatment of FTD and a meta-analysis of treatment studies of antidepressants for the behavioral symptoms of FTD. Results: Patients with FTD show deficiencies in the serotonin and dopamine neurotransmitter systems, while the acetylcholine system appears relatively intact. Antidepressant treatment significantly improves behavioral symptoms in FTD, but most studies are small and uncontrolled. Serotonergic treatments appear to improve the behavioral but not cognitive symptoms of FTD. Conclusions: Studies of neurotransmitter deficiencies in frontotemporal dementia (FTD) can be helpful in developing treatments. Treatment studies on FTD are scarce, given the prevalence and severity of this illness. Larger, well-controlled treatment studies are required to reach more definitive conclusions about treatment efficacy. Multicenter studies are likely the best way to complete treatment studies in a timely manner.

UR - http://www.scopus.com/inward/record.url?scp=33645814682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645814682&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000191304.55196.4d

DO - 10.1212/01.wnl.0000191304.55196.4d

M3 - Review article

VL - 66

SP - 17

EP - 22

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 1

ER -